Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats. / Melander, Simone Anna; Møller, Alexandra Louise; Mohamed, Khaled Elhady; Rasmussen, Daniel Guldager Kring; Genovese, Federica; Karsdal, Morten Asser; Henriksen, Kim; Larsen, Anna Thorsø.

In: American journal of physiology. Endocrinology and metabolism, Vol. 325, No. 5, 2023, p. E529-E539.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Melander, SA, Møller, AL, Mohamed, KE, Rasmussen, DGK, Genovese, F, Karsdal, MA, Henriksen, K & Larsen, AT 2023, 'Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats', American journal of physiology. Endocrinology and metabolism, vol. 325, no. 5, pp. E529-E539. https://doi.org/10.1152/ajpendo.00245.2023

APA

Melander, S. A., Møller, A. L., Mohamed, K. E., Rasmussen, D. G. K., Genovese, F., Karsdal, M. A., Henriksen, K., & Larsen, A. T. (2023). Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats. American journal of physiology. Endocrinology and metabolism, 325(5), E529-E539. https://doi.org/10.1152/ajpendo.00245.2023

Vancouver

Melander SA, Møller AL, Mohamed KE, Rasmussen DGK, Genovese F, Karsdal MA et al. Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats. American journal of physiology. Endocrinology and metabolism. 2023;325(5):E529-E539. https://doi.org/10.1152/ajpendo.00245.2023

Author

Melander, Simone Anna ; Møller, Alexandra Louise ; Mohamed, Khaled Elhady ; Rasmussen, Daniel Guldager Kring ; Genovese, Federica ; Karsdal, Morten Asser ; Henriksen, Kim ; Larsen, Anna Thorsø. / Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats. In: American journal of physiology. Endocrinology and metabolism. 2023 ; Vol. 325, No. 5. pp. E529-E539.

Bibtex

@article{b53bd27310454582b6088f12455daf49,
title = "Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats",
abstract = "Dual amylin and calcitonin receptor agonists (DACRAs) are effective treatments for obesity and type 2 diabetes (T2D). They provide beneficial effects on body weight, glucose control, and insulin action. However, whether DACRAs protect against diabetes-related kidney damage remains unknown. We characterize the potential of long-acting DACRAs (KBP-A, Key Bioscience Peptide-A) as a treatment for T2D-related pathological alterations of the kidney extracellular matrix (ECM) in Zucker diabetic fatty rats (ZDF). We examined levels of endotrophin (profibrotic signaling molecule reflecting collagen type VI formation) and tumstatin (matrikine derived from collagen type IVα3) in serum and evaluated kidney morphology and collagen deposition in the kidneys. We included a study in obese Sprague-Dawley rats to further investigate the impact of KBP-A on ECM biomarkers. In ZDF vehicles, levels of endotrophin and tumstatin increased, suggesting disease progression along with an increase in blood glucose levels. These rats also displayed damage to their kidneys, which was evident from the presence of collagen formation in the medullary region of the kidney. Interestingly, KBP-A treatment attenuated these increases, resulting in significantly lower levels of endotrophin and tumstatin than the vehicle. Levels of endotrophin and tumstatin were unchanged in obese Sprague-Dawley rats, supporting the relation to diabetes-related kidney complications. Furthermore, KBP-A treatment normalized collagen deposition in the kidney while improving glucose control. These studies confirm the beneficial effects of DACRAs on biomarkers associated with kidney fibrosis. Moreover, these antifibrotic effects are likely associated with improved glucose control, highlighting KBP-A as a promising treatment of T2D and its related late complications.NEW & NOTEWORTHY These studies describe the beneficial effects of using a dual amylin and calcitonin receptor agonist (DACRA) for diabetes-related kidney complications. DACRA treatment reduced levels of serological biomarkers associated with kidney fibrosis. These reductions were further reflected by reduced collagen expression in diabetic kidneys. In general, these results validate the use of serological biomarkers while demonstrating the potential effect of DACRAs in treating diabetes-related long-term complications.",
keywords = "DACRA, endotrophin, kidney fibrosis, tumstastin, type 2 diabetes",
author = "Melander, {Simone Anna} and M{\o}ller, {Alexandra Louise} and Mohamed, {Khaled Elhady} and Rasmussen, {Daniel Guldager Kring} and Federica Genovese and Karsdal, {Morten Asser} and Kim Henriksen and Larsen, {Anna Thors{\o}}",
year = "2023",
doi = "10.1152/ajpendo.00245.2023",
language = "English",
volume = "325",
pages = "E529--E539",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "5",

}

RIS

TY - JOUR

T1 - Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats

AU - Melander, Simone Anna

AU - Møller, Alexandra Louise

AU - Mohamed, Khaled Elhady

AU - Rasmussen, Daniel Guldager Kring

AU - Genovese, Federica

AU - Karsdal, Morten Asser

AU - Henriksen, Kim

AU - Larsen, Anna Thorsø

PY - 2023

Y1 - 2023

N2 - Dual amylin and calcitonin receptor agonists (DACRAs) are effective treatments for obesity and type 2 diabetes (T2D). They provide beneficial effects on body weight, glucose control, and insulin action. However, whether DACRAs protect against diabetes-related kidney damage remains unknown. We characterize the potential of long-acting DACRAs (KBP-A, Key Bioscience Peptide-A) as a treatment for T2D-related pathological alterations of the kidney extracellular matrix (ECM) in Zucker diabetic fatty rats (ZDF). We examined levels of endotrophin (profibrotic signaling molecule reflecting collagen type VI formation) and tumstatin (matrikine derived from collagen type IVα3) in serum and evaluated kidney morphology and collagen deposition in the kidneys. We included a study in obese Sprague-Dawley rats to further investigate the impact of KBP-A on ECM biomarkers. In ZDF vehicles, levels of endotrophin and tumstatin increased, suggesting disease progression along with an increase in blood glucose levels. These rats also displayed damage to their kidneys, which was evident from the presence of collagen formation in the medullary region of the kidney. Interestingly, KBP-A treatment attenuated these increases, resulting in significantly lower levels of endotrophin and tumstatin than the vehicle. Levels of endotrophin and tumstatin were unchanged in obese Sprague-Dawley rats, supporting the relation to diabetes-related kidney complications. Furthermore, KBP-A treatment normalized collagen deposition in the kidney while improving glucose control. These studies confirm the beneficial effects of DACRAs on biomarkers associated with kidney fibrosis. Moreover, these antifibrotic effects are likely associated with improved glucose control, highlighting KBP-A as a promising treatment of T2D and its related late complications.NEW & NOTEWORTHY These studies describe the beneficial effects of using a dual amylin and calcitonin receptor agonist (DACRA) for diabetes-related kidney complications. DACRA treatment reduced levels of serological biomarkers associated with kidney fibrosis. These reductions were further reflected by reduced collagen expression in diabetic kidneys. In general, these results validate the use of serological biomarkers while demonstrating the potential effect of DACRAs in treating diabetes-related long-term complications.

AB - Dual amylin and calcitonin receptor agonists (DACRAs) are effective treatments for obesity and type 2 diabetes (T2D). They provide beneficial effects on body weight, glucose control, and insulin action. However, whether DACRAs protect against diabetes-related kidney damage remains unknown. We characterize the potential of long-acting DACRAs (KBP-A, Key Bioscience Peptide-A) as a treatment for T2D-related pathological alterations of the kidney extracellular matrix (ECM) in Zucker diabetic fatty rats (ZDF). We examined levels of endotrophin (profibrotic signaling molecule reflecting collagen type VI formation) and tumstatin (matrikine derived from collagen type IVα3) in serum and evaluated kidney morphology and collagen deposition in the kidneys. We included a study in obese Sprague-Dawley rats to further investigate the impact of KBP-A on ECM biomarkers. In ZDF vehicles, levels of endotrophin and tumstatin increased, suggesting disease progression along with an increase in blood glucose levels. These rats also displayed damage to their kidneys, which was evident from the presence of collagen formation in the medullary region of the kidney. Interestingly, KBP-A treatment attenuated these increases, resulting in significantly lower levels of endotrophin and tumstatin than the vehicle. Levels of endotrophin and tumstatin were unchanged in obese Sprague-Dawley rats, supporting the relation to diabetes-related kidney complications. Furthermore, KBP-A treatment normalized collagen deposition in the kidney while improving glucose control. These studies confirm the beneficial effects of DACRAs on biomarkers associated with kidney fibrosis. Moreover, these antifibrotic effects are likely associated with improved glucose control, highlighting KBP-A as a promising treatment of T2D and its related late complications.NEW & NOTEWORTHY These studies describe the beneficial effects of using a dual amylin and calcitonin receptor agonist (DACRA) for diabetes-related kidney complications. DACRA treatment reduced levels of serological biomarkers associated with kidney fibrosis. These reductions were further reflected by reduced collagen expression in diabetic kidneys. In general, these results validate the use of serological biomarkers while demonstrating the potential effect of DACRAs in treating diabetes-related long-term complications.

KW - DACRA

KW - endotrophin

KW - kidney fibrosis

KW - tumstastin

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85174752248&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00245.2023

DO - 10.1152/ajpendo.00245.2023

M3 - Journal article

C2 - 37792041

AN - SCOPUS:85174752248

VL - 325

SP - E529-E539

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 5

ER -

ID: 372517378